Cancer Family
Gastric Neoplasm
CI-CAN-00000185Explore in graph →
Non-malignant720 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000185Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03615326 | Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) | completed | Phase 3 | 738 | Merck Sharp & Dohme LLCINDUSTRY | 20 | Aug 26, 2026 | clinicaltrials |
| NCT01882933 | D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma(GASTRICHIP) | completed | Phase 3 | 367 | Hospices Civils de LyonOTHER |
| 2 |
| Aug 24, 2026 |
| clinicaltrials |
| NCT03399110 | XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC) | completed | Phase 3 | 1,024 | Fudan UniversityOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05052801 | Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression(FORTITUDE-101) | completed | Phase 3 | 547 | AmgenINDUSTRY | 37 | May 27, 2026 | clinicaltrials |
| NCT03221426 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | completed | Phase 3 | 1,007 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Mar 9, 2026 | clinicaltrials |
| NCT04882241 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension | completed | Phase 3 | 120 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT03675737 | Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) | completed | Phase 3 | 1,579 | Merck Sharp & Dohme LLCINDUSTRY | 33 | Feb 27, 2026 | clinicaltrials |
| NCT07437573 | Oncometabolic Surgery(KLASS-09) | completed | Phase 3 | 94 | Korea University Guro HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT03013010 | PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy(PREACT) | completed | Phase 3 | 204 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT03223376 | A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)(FRUTIGA) | completed | Phase 3 | 703 | Hutchison Medipharma LimitedINDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer(CheckMate649) | completed | Phase 3 | 2,031 | Bristol-Myers SquibbINDUSTRY | 29 | Aug 7, 2025 | clinicaltrials |
| NCT01815853 | Neoadjuvant Chemoradiotherapy vs. Chemotherapy Followed by Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer(Neo-CRAG) | completed | Phase 3 | 620 | Sun Yat-sen UniversityOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT04082364 | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer(MAHOGANY) | completed | Phase 2 / Phase 3 | 82 | MacroGenicsINDUSTRY | 9 | Jun 8, 2025 | clinicaltrials |
| NCT04032119 | RCT of Gastric ESD With or Without Epineprhine Added Solution | completed | Phase 3 | 800 | Chinese University of Hong KongOTHER | 4 | May 4, 2025 | clinicaltrials |
| NCT02349412 | Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers | completed | Phase 3 | 405 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT04499924 | Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer(MOUNTAINEER-02) | completed | Phase 2 / Phase 3 | 17 | Seagen Inc.INDUSTRY | 6 | Jan 22, 2025 | clinicaltrials |
| NCT02578368 | Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction(FLOT5) | completed | Phase 3 | 183 | Krankenhaus NordwestOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT02845479 | The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I(POISE) | completed | Phase 3 | 22 | The Canadian College of Naturopathic MedicineOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT00400179 | A Safety and Efficacy Study in Patients With Gastric Cancer | completed | Phase 3 | 1,053 | Taiho Oncology, Inc.INDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT02500043 | Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer | completed | Phase 3 | 507 | Taiho Oncology, Inc.INDUSTRY | 18 | Sep 3, 2024 | clinicaltrials |
| NCT01839773 | Phase 3 Study to Compare Efficacy and Safety of DHP107 vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer(DREAM) | completed | Phase 3 | 238 | Daehwa Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 25, 2024 | clinicaltrials |
| NCT02267343 | Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer | completed | Phase 3 | 493 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 3 | May 3, 2024 | clinicaltrials |
| NCT02746796 | Study of ONO-4538 in Gastric Cancer | completed | Phase 2 / Phase 3 | 680 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 3 | May 3, 2024 | clinicaltrials |
| NCT03006705 | Study of Adjuvant ONO-4538 With Resected Gastric Cancer | completed | Phase 3 | 800 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 4 | May 3, 2024 | clinicaltrials |
| NCT01924533 | Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. | completed | Phase 3 | 525 | AstraZenecaINDUSTRY | 4 | Mar 22, 2024 | clinicaltrials |
| NCT03607656 | The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer(CHANGE) | completed | Phase 2 / Phase 3 | 270 | Shanghai University of Traditional Chinese MedicineOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT01515748 | Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer(PRODIGY) | completed | Phase 3 | 530 | SanofiINDUSTRY | 1 | Dec 13, 2023 | clinicaltrials |
| NCT02178956 | A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer(BRIGHTER) | completed | Phase 3 | 714 | Sumitomo Pharma America, Inc.INDUSTRY | 22 | Nov 15, 2023 | clinicaltrials |
| NCT02853474 | Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy(EPIC-1511) | completed | Phase 3 | 480 | Centre Oscar LambretOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT02494583 | Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) | completed | Phase 3 | 763 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 13, 2023 | clinicaltrials |
| NCT03745170 | Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer | completed | Phase 3 | 650 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 1, 2023 | clinicaltrials |
| NCT02661971 | FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)(RAMSES/FLOT7) | completed | Phase 2 / Phase 3 | 180 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 2 | Jul 11, 2022 | clinicaltrials |
| NCT03042611 | A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer(ANGEL) | completed | Phase 3 | 460 | Elevar TherapeuticsINDUSTRY | 12 | Jul 8, 2022 | clinicaltrials |
| NCT02898077 | A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer | completed | Phase 3 | 440 | Eli Lilly and CompanyINDUSTRY | 4 | Jun 14, 2022 | clinicaltrials |
| NCT02370498 | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) | completed | Phase 3 | 592 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 6, 2022 | clinicaltrials |
| NCT03130790 | Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) | completed | Phase 2 / Phase 3 | 52 | ASLAN PharmaceuticalsOTHER | 8 | Feb 15, 2022 | clinicaltrials |
| NCT02322593 | Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer(SOLAR) | completed | Phase 3 | 711 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 2 | Dec 20, 2021 | clinicaltrials |
| NCT02395640 | The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer | completed | Phase 3 | 438 | Fudan UniversityOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT02314117 | A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer(RAINFALL) | completed | Phase 3 | 645 | Eli Lilly and CompanyINDUSTRY | 20 | Aug 26, 2021 | clinicaltrials |
| NCT02158988 | Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis(GASTRIPEC) | completed | Phase 3 | 105 | Charite University, Berlin, GermanyOTHER | 1 | Jul 29, 2021 | clinicaltrials |
| NCT03196791 | Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient | completed | Phase 3 | 196 | Korea University Anam HospitalOTHER | 1 | Jul 12, 2021 | clinicaltrials |
| NCT00002883 | Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus | completed | Phase 3 | 250 | UNICANCEROTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT01774786 | A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer(JACOB) | completed | Phase 3 | 780 | Hoffmann-La RocheINDUSTRY | 32 | Dec 30, 2020 | clinicaltrials |
| NCT02114359 | Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer | completed | Phase 3 | 111 | Seoul National University HospitalOTHER | 1 | Oct 23, 2020 | clinicaltrials |
| NCT02581462 | FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer(PETRARCA) | completed | Phase 2 / Phase 3 | 81 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Aug 11, 2020 | clinicaltrials |
| NCT00020787 | Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer | completed | Phase 3 | 8 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT02545504 | Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma(GAMMA-1) | completed | Phase 3 | 432 | Gilead SciencesINDUSTRY | 16 | May 26, 2020 | clinicaltrials |
| NCT00052910 | Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer | completed | Phase 3 | 546 | Alliance for Clinical Trials in OncologyOTHER | 2 | May 7, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Aug 26, 2026source: clinicaltrials